Literature DB >> 11096346

Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells.

S Kamazawa1, J Kigawa, Y Minagawa, H Itamochi, M Shimada, M Takahashi, S Sato, R Akeshima, N Terakawa.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the combination effect of paclitaxel (PTX) and cisplatin (CDDP) and to determine the mechanisms of interaction between these agents. METHODS AND
RESULTS: We used human ovarian adenocarcinoma cell lines, namely a parent cell line (KF), a CDDP-resistant cell line (KFr) and a PTX-resistant cell line (KFTx).The combination effect of PTX and CDDP was synergistic on KF and KFTx and additive on KFr. The incidence of anaphase or telophase, evaluated by immunofluorescence microscopy, decreased with PTX and significantly decreased with PTX and CDDP in KF and KFTx. The concentration of PTX, which was measured by high-performance liquid chromatography, was higher in KF and KFTx cells treated with a combination of PTX and CDDP than those treated with PTX alone. Multidrug resistance gene mRNA appeared in KFTx and its expression decreased after exposure to PTX and CDDP. After exposure to CDDP, the expression of multidrug resistance-associated protein (MRP) and the concentration of glutathione increased in KF, but not in KFr or KFTx. MRP expression slightly increased in KF and KFTx after exposure to PTX. In contrast, its expression decreased in KFr.
CONCLUSION: The present study suggests that CDDP enhances PTX accumulation and that the interaction of these agents is synergistic in CDDP-sensitive cells. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096346     DOI: 10.1159/000012191

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.

Authors:  Dirk Theile; Zoltan Gal; Rolf Warta; Juan Pablo Rigalli; Bernd Lahrmann; Niels Grabe; Christel Herold-Mende; Gerhard Dyckhoff; Johanna Weiss
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

2.  A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Donald W Miller
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

3.  A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.

Authors:  A E Guppy; A E Nelstrop; T Foster; R Agarwal; M J Seckl; G J S Rustin
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

4.  Association of drug transporter expression with mortality and progression-free survival in stage IV head and neck squamous cell carcinoma.

Authors:  Rolf Warta; Dirk Theile; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Johanna Weiss; Gerhard Dyckhoff
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

5.  Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.

Authors:  Winyoo Chowanadisai; Shanta M Messerli; Daniel H Miller; Jamie E Medina; Joshua W Hamilton; Mark A Messerli; Alexander S Brodsky
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

6.  Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.

Authors:  Y Komuro; Y Udagawa; N Susumu; D Aoki; T Kubota; S Nozawa
Journal:  Jpn J Cancer Res       Date:  2001-11

7.  (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma.

Authors:  Ting Luo; Jiao Wang; Yancun Yin; Hui Hua; Jing Jing; Xiangming Sun; Minjing Li; You Zhang; Yangfu Jiang
Journal:  Breast Cancer Res       Date:  2010-01-15       Impact factor: 6.466

8.  Modulation of MDR1 and MRP3 gene expression in lung cancer cells after paclitaxel and carboplatin exposure.

Authors:  Consolación Melguizo; Jose Prados; Raquel Luque; Raúl Ortiz; Octavio Caba; Pablo J Alvarez; Beatriz Gonzalez; Antonia Aranega
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

9.  Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.

Authors:  Hiroaki Itamochi; Junzo Kigawa; Habiba Sultana; Takahiro Iba; Ryoji Akeshima; Shunji Kamazawa; Yasunobu Kanamori; Naoki Terakawa
Journal:  Jpn J Cancer Res       Date:  2002-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.